Gemma Navarro

Also affiliated with Biomedical Research Networking Center on Neurodegenerative Diseases, Servicio Navarro de Salud, Institute of Food Science and Technology, Vall d'Hebron Institut de Recerca, Institut Català de Ciències del Clima, Centro de Investigación Biomédica en Red, Universitat de Barcelona, Universidad de Navarra

Biochemistry, Genetics and Molecular BiologyNeuroscienceMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Adenosine/A2B Receptor Signaling Ameliorates the Effects of Aging and Counteracts Obesity”.

Adenosine/A2B Receptor Signaling Ameliorates the Effects of Aging and Counteracts Obesity

Cell Metabolism(2020)10.1016/j.cmet.2020.06.006

N/A

0DataRank · unranked

121 citations

Gemma Navarro, Minna Lahesmaa, Laia Reverte-Salisa, Francesca Copperi, Arnau Cordomí +26 more

Uncovering the role of G9a modulatory landscape promoting neuronal plasticity and neuroprotection in Alzheimer's disease

Research Square(2022)10.21203/rs.3.rs-1228952/v1

N/A

0DataRank · unranked

0 citations

Pedro Antonio Ávila-López, Júlia Companys‐Alemany, Gemma Navarro, Laura Marsal-García, Raquel Larramona‐Arcas +8 more

Progress on the development of Class A GPCR‐biased ligands

British Journal of Pharmacology(2024)10.1111/bph.17301

N/A

0DataRank · unranked

18 citations

Magdalena M. Scharf, Marcel Bermúdez, Attila Egyed, Rafael Franco, Olivia Kramer Hansen +16 more

G9a Inhibition Promotes Neuroprotection through GMFB Regulation in Alzheimer’s Disease

Aging and Disease(2024)10.14336/ad.2023.0424-2

N/A

0DataRank · unranked

22 citations

Qizhi Geng, Gemma Navarro, Pedro Antonio Ávila-López, Júlia Companys‐Alemany, Laura Marsal-García +12 more

First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease

Molecular Therapy(2025)10.1016/j.ymthe.2025.12.038

N/A

0DataRank · unranked

2 citations

David Valle-Garcia, Carla Barbaraci, Fernando Romero-Becerra, Rohit Kumar Singh, Júlia Jarne-Ferrer +34 more